Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

A powerful new lab-made opioid is moving through the illegal US drug supply, and federal officials warn it could keep spreading. The drug, called cychlorphine, may be up to 10 times stronger than ...

The new biosimilar offers an additional treatment option for patients with multiple myeloma, bone metastases, and giant cell tumors of the bone.

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

The oral ALK2 inhibitor significantly reduced mean total new heterotopic ossification volume at 24 weeks in patients aged 12 ...

FDA approval of Emcitate (tiratricol) offers the first targeted therapy for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 deficiency.

Betzaida Tejada-Vera, from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from all death certificates filed in the 50 states and the District of Columbia ...

Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.

Modest decline seen in 30-day case fatality rates over time among young adults, driven by intracerebral hemorrhage, subarachnoid hemorrhage.

Daiichi Sankyo and Merck have voluntarily withdrawn their application for ifinatamab deruxtecan in pretreated extensive-stage small cell lung cancer following feedback from the FDA regarding phase 2 ...

Advisers split on whether Galleri, which screens for more than 50 cancers, catches disease early enough to save lives.

Phase 3 trial data show significant scalp, eyelash, and eyebrow hair regrowth at 36 weeks in adolescents treated with oral baricitinib.